Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer (ABC)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Genentech
Celgene Corporation
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00479674
First received: May 25, 2007
Last updated: July 19, 2013
Last verified: July 2013
  Purpose

Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. Monoclonal antibodies including bevacizumab target vascular endothelial growth factor (VEGF) to reduce angiogenesis. We hypothesize that the previously-untested combination of weekly Abraxane® and carboplatin plus biweekly bevacizumab will lengthen time to progression without producing intolerable toxicity.


Condition Intervention Phase
Breast Cancer
Drug: Abraxane
Drug: Bevacizumab
Drug: Carboplatin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • To assess the safety and tolerability of a combination regimen of weekly Abraxane® and carboplatin plus biweekly bevacizumab to treat women with Stage IV or inoperable Stage III "triple negative" metastatic breast cancer. [ Time Frame: On-going ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Clinical: To assess progression-free survival(PFS) in measurable disease patients according to Response Evaluation Criteria(RECIST) in Solid Tumors criteria. [ Time Frame: on-going ] [ Designated as safety issue: No ]
  • To evaluate sequential plasma samples for presence of selected angiogenic markers [ Time Frame: on-going ] [ Designated as safety issue: No ]
  • to determine if apolipoprotein alleles (apo-E) correlate with treatment-related neuropathy [ Time Frame: on-going ] [ Designated as safety issue: No ]
  • to determine if SPARC expression in breast tumors predicts progression-free survival (PFS) [ Time Frame: on-going ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: May 2007
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Abraxane, Carboplatin, Bevacizumab
Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
Drug: Abraxane
100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
Other Name: nanoparticle albumin-bound paclitaxel
Drug: Bevacizumab
10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
Other Name: Avastin
Drug: Carboplatin
area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.

Detailed Description:

Anthracycline-based chemotherapy is widely used as adjuvant treatment for breast cancer. In addition to the challenge posed by anthracycline-induced cardiotoxicity, there are issues surrounding previous treatment with anthracyclines which limit its utility in the metastatic disease setting. Many patients with advanced disease will have had prior anthracycline-based adjuvant therapy, may have reached a maximum cumulative lifetime dose, or developed refractory disease, creating an obvious need for non-anthracycline treatment strategies.3 Platinum- and taxane-based chemotherapies as first-line therapy for metastatic breast cancer have demonstrated significant activity, producing single-agent response rates > 50%; in combination these rates increased to > 60% in both previously untreated and in patients who previously received anthracyclines.3 However, overall survival has remained relatively unchanged.4 As there is currently no standard of care for patients with metastatic breast cancer, various physical and psychological factors must be considered when evaluating chemotherapy treatment options, including the patient's tumor biology and growth rate, presence and extent of metastases, history of prior treatment and response, sensitivity and tolerance to therapy, and quality of life.2 Strategies to develop combination, higher dose, or sequential regimens using these active agents, while improving response rates and/or time to progression, may produce increased toxicity without increased survival.2 Because metastatic breast cancer remains essentially incurable using cytotoxic therapy alone, the study of targeted biologics offers new opportunities to enhance drug delivery via their ability to regulate specific receptors that are associated with clinically aggressive disease processes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Tissue block containing tumor to confirm metastatic breast cancer is required;
  • Measurable disease according to RECIST criteria
  • "Triple negative" disease defined as tumor demonstrating no expression for estrogen, progesterone or human epidermal growth factor receptor 2(HER2)receptors. "No expression" is categorized as ≤ 10% of cells staining or Allred ≤ 2;
  • Aged 18 years or older;
  • Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0 or 1; life expectancy ≥ 3 months;
  • Patients may have received 0 - 1 prior therapies (except taxanes in the metastatic setting). An interval of at least 1 week must have elapsed since prior chemotherapy or hormonal therapy for metastatic disease; at least 6 months must have elapsed since prior adjuvant therapy;
  • ≥ 2 weeks between surgery and study enrollment (≥ 4 weeks between major surgery (defined as open abdominal/thoracic/cardiac) and study enrollment;
  • Laboratory tests performed within 14 days of study entry:

    • Granulocytes ≥ 1,500/µL;
    • Platelets ≥ 100,000/µL;
    • Hemoglobin ≥ 9 gm/dL;
    • Total bilirubin ≤ institutional upper limit of normal (ULN);
    • Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 5 times ULN;

      • Alkaline phosphatase ≤ 2.5 times ULN;
    • Estimated creatinine clearance ≥ 60 mL/min.
  • left ventricular ejection fraction (LVEF)≥ 50% by multigated acquisition (MUGA)/Echocardiogram;
  • Informed consent to receive protocol treatment, to provide biologic specimens, and to complete neurotoxicity questionnaires;
  • Cognitive and communication skills to comply with study and/or follow-up procedures;
  • No reproductive potential:

    • If pre-menopausal: Negative serum pregnancy test and patient agreement to use adequate contraceptive method (abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during and for 3 months after completion of treatment.
    • If post-menopausal: Amenorrhea for ≥ 12 months.

Exclusion Criteria:

  • Pregnant or breast feeding;
  • Prior treatment with Abraxane®, carboplatin or bevacizumab, or any taxane for metastatic breast cancer;
  • Known hypersensitivity to any component of any study drug;
  • Active infection;
  • Current neuropathy ≥ grade 2;
  • central nervous system (CNS) metastases as determined by head CT with contrast;
  • History of bleeding within the past 6 months or active bleeding disorder;
  • Serious non-healing wound, ulcer or bone fracture;
  • Uncontrolled congestive heart failure (CHF), or history of myocardial infarction(MI), unstable angina, stroke, or transient ischemia within previous 6 months;
  • Inadequately controlled hypertension (defined as systolic blood pressure < 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications; prior history of hypertensive crisis or hypertensive encephalopathy;
  • Proteinuria (defined as urine protein: creatinine (UPC) ratio ≥ 1.0 or urine dipstick ≥ 2+.
  • Significant vascular disease (aortic aneurysm, aortic dissection) or symptomatic peripheral vascular disease;
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within previous 6 months;
  • Uncontrolled serious contraindicated medical condition or psychiatric illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00479674

Locations
United States, North Carolina
Presbyterian Health Care
Charlotte, North Carolina, United States, 28204
Northeast Oncology Associates
Concord, North Carolina, United States, 28205
Duke University Medical Center
Durham, North Carolina, United States, 27710
Forsyth Regional Cancer Center
Winston-Salem, North Carolina, United States, 27103-3019
Sponsors and Collaborators
Duke University
Genentech
Celgene Corporation
Investigators
Principal Investigator: Kimberly Blackwell, MD Duke University
  More Information

No publications provided

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00479674     History of Changes
Other Study ID Numbers: Pro00014837, AVF3962s
Study First Received: May 25, 2007
Last Updated: July 19, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Duke University:
Metastatic Breast Cancer
Advanced Breast Cancer
Hormone Receptor AND Her2/neu Negative
Triple Negative
Triple Negative Breast Cancer
Stage IV or Inoperable Stage III Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Bevacizumab
Carboplatin
Paclitaxel
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on August 01, 2014